U‐500 insulin: why, when and how to use in clinical practice
- 16 November 2006
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 23 (4) , 265-268
Abstract
Some patients with type 2 diabetes mellitus (T2DM) have severe insulin resistance. Their insulin requirements are significantly greater. These patients need to take 2–3 injections at the same time to take the correct insulin dose or to redial the insulin pen. When daily insulin requirements are in excess of 300 units/day, the volume of the injected insulin becomes an issue. Large‐volume injection can cause discomfort and lead to poor concordance with treatment. Using high‐strength insulin e.g. U‐500 insulin can reduce the volume of the injected insulin. Despite publications of small case reports or case series, no universal guidelines exist on the use of U‐500 insulin. We discuss common sense approaches when considering the use of U‐500 insulin in clinical practice. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 10 references indexed in Scilit:
- Use of U-500 Regular Insulin in Type 2 DiabetesDiabetes Care, 2006
- Use of U-500 Regular Insulin by Continuous Subcutaneous Insulin Infusion in Patients with Type 2 Diabetes and Severe Insulin ResistanceEndocrine Practice, 2006
- Analysis of Effectiveness of Human U-500 Insulin in Patients Unresponsive to Conventional Insulin TherapyEndocrine Practice, 2005
- The Use of U-500 in Patients With Extreme Insulin ResistanceDiabetes Care, 2005
- A Novel Use of U-500 Insulin for Continuous Subcutaneous Insulin Infusion in Patients with Insulin Resistance: A Case SeriesEndocrine Practice, 2003
- Drop that insulin syringeNursing, 2002
- Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigsDiabetes Research and Clinical Practice, 2000
- Insulin Resistance and the Use of U-500 Insulin: A Case ReportThe Diabetes Educator, 1987
- Enhanced efficacy of U-500 insulin in the treatment of insulin resistance caused by target tissue insensitivityThe American Journal of Medicine, 1984
- U-500 Insulin in the Treatment of Antibody-Mediated Insulin ResistanceAnnals of Internal Medicine, 1981